Selling the Story of a Discovery

Magnus Höök, a professor at Texas A&M, worked for more than 20 years perfecting an antibody that attacks protein adhesins on bacterial surfaces. But when Höök and his colleagues sought to move their trademark proteins into the market, he says his "lack of knowledge" surprised him. "You start out thinking this is a cool idea, and it would be useful," Höök relates. Höök is a director at Inhibitex Inc., an Alpharetta, Ga.-based company that is now testin

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Many scientists loathe any association with such commercial considerations Höök observes, and indeed, even Lita Nelson, director of the Technology Licensing Office of the Massachusetts Institute of Technology, takes pains to distance academic enterprise from pure entrepreneurship. "Most universities see technology transfer primarily as a way of getting very early stage technology invested in," she says. "They recognize the high risk. It is not primarily a money-making proposition for most universities, ... but instead a way of getting their funding for basic research into practical use by the public."

Editor's Note: Parts 2 and 3 of Taking a Discovery to Market will appear in the Nov. 26 and Dec. 10 issues.

But product development requires private finance. Before Höök could get development funds, he had to replace his focus on the basic research with an emphasis on the story, the market-based justification of investment in an innovation. That story can ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Paula Park

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours